Riche M C, Hadjean E, Tran-Ba-Huy P, Merland J J
Plast Reconstr Surg. 1983 May;71(5):607-14. doi: 10.1097/00006534-198305000-00003.
We present our early experience in the treatment of cutaneous capillary-venous malformations using a new fibrosing agent called Ethibloc. Superselective angiography was used to delineate the vascular anomaly and effect temporary occlusion. Whenever possible, compression of venous outflow also was used, while the sclerosing agent was injected directly into the malformation by percutaneous puncture. Sixteen patients with capillary-venous malformations have been treated with this agent since 1979. A mild local inflammatory reaction was noted in some cases; there were no instances of skin necrosis. In 10 patients, the fibrosed vascular malformation was excised, and in 6 patients, the area of vascular anomaly decompressed to such a degree that resection was unnecessary.
我们介绍了使用一种名为Ethibloc的新型纤维化剂治疗皮肤毛细血管-静脉畸形的早期经验。采用超选择性血管造影来描绘血管异常并实现临时闭塞。只要有可能,还会采用静脉流出道压迫,同时通过经皮穿刺将硬化剂直接注入畸形部位。自1979年以来,已有16例毛细血管-静脉畸形患者接受了该药物治疗。在某些病例中观察到轻微的局部炎症反应;未出现皮肤坏死的情况。10例患者切除了纤维化的血管畸形,6例患者血管异常区域减压至无需切除的程度。